Sarepta Therapeutics, Inc. (NASDAQ:SRPT) SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total transaction of $575,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shamim Ruff also recently made the following trade(s):

  • On Friday, July 21st, Shamim Ruff sold 12,138 shares of Sarepta Therapeutics stock. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86.

Sarepta Therapeutics, Inc. (NASDAQ SRPT) traded up 0.96% during midday trading on Thursday, reaching $50.26. 950,168 shares of the company’s stock were exchanged. The stock’s market cap is $3.23 billion. Sarepta Therapeutics, Inc. has a 12 month low of $26.26 and a 12 month high of $61.99. The firm has a 50 day moving average of $43.21 and a 200-day moving average of $36.18.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. During the same quarter in the previous year, the business earned ($1.19) earnings per share. The firm’s revenue was up 350000.0% on a year-over-year basis. On average, equities research analysts predict that Sarepta Therapeutics, Inc. will post ($1.22) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics, Inc. (SRPT) SVP Sells $575,000.00 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/sarepta-therapeutics-inc-srpt-svp-sells-575000-00-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of SRPT. BlackRock Inc. grew its position in Sarepta Therapeutics by 4,403.1% during the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after acquiring an additional 5,175,193 shares during the last quarter. Camber Capital Management LLC bought a new position in shares of Sarepta Therapeutics in the first quarter worth approximately $39,960,000. State Street Corp grew its holdings in shares of Sarepta Therapeutics by 21.2% in the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after purchasing an additional 559,342 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Sarepta Therapeutics by 2,786.1% in the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after purchasing an additional 548,826 shares during the last quarter. Finally, HealthCor Management L.P. grew its holdings in shares of Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares during the last quarter. Institutional investors and hedge funds own 65.41% of the company’s stock.

A number of analysts have recently issued reports on the stock. Credit Suisse Group restated an “outperform” rating and set a $81.00 target price on shares of Sarepta Therapeutics in a research note on Monday. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Leerink Swann reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 3rd. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $96.00 price objective (down previously from $102.00) on shares of Sarepta Therapeutics in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have issued a buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and an average target price of $62.79.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.